Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

May 21, 2024

https://www.globenewswire.com/news-release/2024/05/21/2885561/0/en/Kronos-Bio-Appoints-Deborah-Knobelman-Ph-D-as-Chief-Operating-Officer-and-Chief-Financial-Officer.html

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.